Nanotechnology and Oncology Workshop Summary (2011) / Chapter Skim
Currently Skimming:
B Speaker and Planning Committee Biographies
B Speaker and Planning Committee Biographies
Pages 89-106
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 89... ...
; planned and initiated an NCI-wide program to establish biospecimen standards and best practices; and planned and launched the Clinic Proteomics Technology Initiative for Cancer that is focused on the development, standardization, and deployment of the technologies, reagents, and protocols needed to enable the systematic and reproducible identification of cancer biomarkers. She also co-developed The Cancer Genome Atlas (TCGA)
|
From page 90... ...
She served as a senior executive at Battelle Memorial Institute for 18 years where she developed and led large groups of scientists and technical staff working in drug discovery and development, pharmacology, clinical trials, and biotechnology, including several NCI sponsored research programs. As a Senior Vice President at Battelle, she pioneered several programs in cancer research in collaboration with the NCI, including the use of advanced research models for evaluating new drug candidates and novel models for pharmacologic and toxicological evaluation.
|
From page 91... ...
Curley, M.D., is Professor of Surgery, the Charles B Barker Chair in Surgery, Program Director of the Gastrointestinal Multidisciplinary Care Center, Chief of Gastrointestinal Tumor Surgery, and Director of the Surgical Oncology Fellowship Program at the University of Texas MD Anderson Cancer Center.
|
From page 92... ...
Dr. Curley is a Fellow of the American College of Surgeons and serves in the following groups: Colorectal Cancer Collaborative Clinical Trials, Colorectal Cancer Commission on Cancer Fellowship, Commission on Cancer Liver Disease Site Team, and the American College of Surgeons Hepatobiliary Oncology Group.
|
From page 93... ...
He is also a member of the Editorial Boards for the following journals: Annals of Surgical Oncology, The Cancer Bulletin, International Journal of Surgical Sciences, Cancer Reports, Bulletin of the National Cancer Institute of Italy, European Journal of Surgical Science, International Journal of Surgical Investigation.
|
From page 94... ...
BVS was acquired by Guidant Corporation in 2003 and these stents are now being evaluated in a series of international clinical trials led by Abbott, enrolling over 1,000 patients as of November 2009, for the treatment of coronary artery disease. With the PRINT technology developed in the DeSimone lab, DeSimone's group is now heavily focused on bringing the precision, uniformity, and mass production techniques associated with the fabrication of nanoscale features found in the microelectronics industry to the nanomedicine field for the fabrication and delivery of vaccines and therapeutics for the treatment and prevention of diseases.
|
From page 95... ...
She has contributed more than 250 scientific articles and patents, and has been a recipient of many awards including the Pfizer Research Award for Pharmaceutical Sciences, Young Investigator Award of the Controlled Release Society, the Interdisciplinary Award of the Royal Society for Chemistry UK, the Berlin-Brandenburg Academy of Sciences Monika Knutzner Award for Innovative Cancer Research, a Princess Takamatsu Cancer Foundation Lecturer, and the GSK International Achievement Award. In 2009, she received The APSTJ Nagai International Woman Scientist Award and was made a Fellow of the Association of Pharmaceutical Science and Technology (APSTJ)
|
From page 96... ...
Dr. Ferrari also served as Special Expert on Nanotechnology at the National Cancer Institute in 2003–2005, providing leadership into the formulation, refinement, and approval of the NCI's Alliance for Nanotechnology in Cancer, currently the world's largest program in medical nanotechnology.
|
From page 97... ...
that concluded the political agreement on the European Clinical Trials Directive (2000)
|
From page 98... ...
The Institute's resources are helping scientists to accelerate the pace of discovery and the translation of findings to the clinic and community, advancing MD Anderson's mission in cancer prevention research, practice, and education.
|
From page 99... ...
Gilloon Professor and Professor of Chemistry at Caltech, and Professor of Molecular & Medical Pharmacology at UCLA, and Director of the National Cancer Institute's NanoSystems Biology Cancer Center. Heath received a B.Sc.
|
From page 100... ...
, an international, multi-stakeholder organization whose mission is to develop and communicate information regarding potential environmental and health risks of nanotechnology thereby fostering risk reduction while maximizing societal benefit. She has experience as a chemical researcher, educator, curriculum developer, administrator, outreach coordinator, and policy fellow.
|
From page 101... ...
Dr. Li is currently a Professor of Radiology at Weill Medical College of Cornell University and MD Anderson Foundation Distinguished Chair of Radiology at the Methodist Hospital in Houston, Texas.
|
From page 102... ...
prior to becoming a Clinical Investigator and then Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch, NCI. He is currently the Director of the Montefiore-Einstein Center for Cancer Care, Associate Director of the Albert Einstein Cancer Center, and Professor and ViceChairman of Surgery and Professor of Genetics at the Montefiore Medical Center and the Albert Einstein College of Medicine in New York.
|
From page 103... ...
John Mendelsohn, M.D., combines experience in clinical and laboratory research with administrative expertise in preparing the University of Texas MD Anderson Cancer Center for the next century. Since becoming president in 1996, he has recruited a visionary management team and implemented new priorities for integrated programs in patient care, research, education, and cancer prevention.
|
From page 104... ...
He was instrumental in establishing and funding a National Cancer Institute–designated Cancer Center at UCSD, which he directed from its inception in 1976 until he went to Memorial Sloan-Kettering Cancer Center in 1985. At Memorial Sloan-Kettering, Dr.
|
From page 105... ...
Dr. Niederhuber also holds a clinical appointment on the NIH Clinical Center Medical Staff.
|
From page 106... ...
He is also the Director of the MGH Center for Molecular Imaging Research, and is clinically active as an Attending Interventional Radiologist in the MGH Department of Radiology. He is an active member of many Boston-area research communities, including the Department of Systems Biology at Harvard Medical School, the Broad Institute of Harvard and the Massachusetts Institute of Technology, the Dana-Farber-Harvard Cancer Center, and the Harvard Stem Cell Institute (HSCI)
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.